Seminars in Hematology
Volume 47 , Pages S18-S20 , April 2010

Status of Ongoing Collaborative Efforts

  • Julie M. Vose

      Affiliations

    • Corresponding Author InformationAddress correspondence to Julie M. Vose, MD, Division of Hematology/Oncology, 987680 Nebraska Medical Center, Omaha, NE 68198-7680

References 

  1. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma: the Non-Hodgkin's Lymphoma Classification Project. Blood. 1997;89:3909–3918
  2. Rizvi MA, Evens AM, Tallman MS, Nelson BP, Rosen ST. T-cell non-Hodgkin lymphoma. Blood. 2006;107:1255–1264
  3. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon, France: IARC Press; 2008;
  4. Costello R, Sanchez C, Le Treut T, Rihet P, Imbert J, Sebahoun G. Peripheral T-cell lymphoma gene expression profiling and potential therapeutic exploitations. Br J Haematol. November 12, 2009;[Epub ahead of print]
  5. Savage KJ. Prognosis and primary therapy in peripheral T-cell lymphomas. Hematol Am Soc Hematol Educ Program. 2008;280–288
  6. Escalon MP, Liu NS, Yang Y, et al. Prognostic factors and treatment of patients with T-cell non-Hodgkin lymphoma: the M.D. Anderson Cancer Center experience. Cancer. 2005;103:2091–2098
  7. Horwitz SM. Novel therapies and role of transplant in the treatment of peripheral T-cell lymphomas. Hematol Am Soc Hematol Educ Program. 2008;289–296
  8. Vose J, Armitage J, Weisenburger D. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol. 2008;26:4124–4130

 STATEMENT OF CONFLICT OF INTEREST: Dr. Vose discloses the following relationships: Contracted Research: GSK, Applied Molecular Evolution, Celgene, Allos, Astellas, Millennium, Genetech, Rigel, Bristol-Myers, Genzyme, Pharmacyclics, Novartis.

PII: S0037-1963(10)00017-X

doi: 10.1053/j.seminhematol.2010.01.016

Seminars in Hematology
Volume 47 , Pages S18-S20 , April 2010

Article Tools